Autopsy report · NCT04609579

Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma

“Sponsor decision (not due to safety concerns)”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 3 years 2 months before it stopped.
• 27 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Stingthera, Inc.

Sponsor type

Industry

Conditions

Advanced Solid Tumor; Advanced Lymphoma

Interventions

SNX281; pembrolizumab

Participants

27

Sites

4

Countries

United States

Trials that died the same way

• NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
  “sponsor decision (not for safety)” (98% match in meaning)
• A Evaluation of 3D Functional MIRA System in Women With Mammographically Dense Breasts
  “Sponsor decision, not safety related” (96% match in meaning)
• A Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown Cause
  “Sponsor decision; Not a safety decision” (95% match in meaning)
• (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
  “Sponsor decision, not related to safety concerns” (93% match in meaning)
• Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients
  “Sponsor decision not related to safety reasons” (90% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.